Urothelial carcinoma of the bladder: Definition, treatment and future efforts

Nature Reviews Urology

Volumn 8, Issue 11, 2011, Pages 631-642

  Prasad, Sandip M ^a   Decastro, G Joel ^b   Steinberg, Gary D ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; BCG VACCINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FOLIC ACID ANTAGONIST; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSTIMULATING AGENT; KEYHOLE LIMPET HEMOCYANIN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; MONOCLONAL ANTIBODY; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR; RUBRATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VINBLASTINE; VINCA ALKALOID; VINFLUNINE;

BLADDER CANCER; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CARDIOTOXICITY; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CYSTECTOMY; DIAGNOSTIC ACCURACY; GENETIC RISK; HUMAN; NONHUMAN; PATIENT IDENTIFICATION; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; RISK FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 81055125378     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.144     Document Type: Review

References (156)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Altekruse, S. F. et al. (Eds). SEER Cancer Statistics Review, 1975-2007 (National Cancer Institute, Bethesda, 2010).
3. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser, R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21, 1315-1330 (2003). (Pubitemid 38041357)
4. Mungan, N. A., Kiemeney, L. A., van Dijck, J. A., van der Poel, H. G. & Witjes, J. A. Gender differences in stage distribution of bladder cancer. Urology 55, 368-371 (2000). (Pubitemid 30110586)
5. Underwood, W. 3rd, Dunn, R. L., Williams, C. & Lee, C. T. Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. J. Am. Coll. Surg. 202, 284-290 (2006). (Pubitemid 43112488)
6. Du, X. L., Lin, C. C., Johnson, N. J. & Altekruse, S. Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. Cancer 117, 3242-3251 (2011).
7. Scosyrev, E., Noyes, K., Feng, C. & Messing, E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115, 68-74 (2009).
8. Katz, M. H. & Steinberg, G. D. Sex and race in bladder cancer: what we have learned and future directions. Cancer 115, 10-12 (2009).
9. Stern, M. C. et al. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res. 69, 6857-6864 (2009).
10. Risch, A., Wallace, D. M., Bathers, S. & Sim, E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 4, 231-236 (1995).
11. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719-724 (2009).
12. Pruthi, R. S., Baldwin, N., Bhalani, V. & Wallen, E. M. Conservative management of low risk superficial bladder tumors. J. Urol. 179, 87-90 (2008). (Pubitemid 350216758)
13. Chang, S. S., Hassan, J. M., Cookson, M. S., Wells, N. & Smith, J. A. Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J. Urol. 170, 1085-1087 (2003). (Pubitemid 37108084)
14. Herr, H. W., Dotan, Z., Donat, S. M. & Bajorin, D. F. Defining optimal therapy for muscle invasive bladder cancer. J. Urol. 177, 437-443 (2007). (Pubitemid 46075130)
15. Allard, P., Bernard, P., Fradet, Y. & Tetu, B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br. J. Urol. 81, 692-698 (1998). (Pubitemid 28316632)
16. Kurth, K. H. et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur. J. Cancer 31A, 1840-1846 (1995).
17. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466-477 (2006).
18. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303-314 (2008).
19. Parmar, M. K., Freedman, L. S., Hargreave, T. B. & Tolley, D. A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J. Urol. 142, 284-288 (1989). (Pubitemid 19197097)
20. Millan-Rodriguez, F., Chechile-Toniolo, G., Salvador-Bayarri, J., Palou, J. & Vicente-Rodriguez, J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol. 163, 73-78 (2000).
21. Shariat, S. F. et al. Nomograms including Nuclear Matrix Protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J. Urol. 173, 1518-1525 (2005). (Pubitemid 40524761)
22. Catto, J. W. F. et al. Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. Clin. Cancer Res. 9, 4172-4177 (2003). (Pubitemid 37204036)
23. Qureshi, K. N., Naguib, R. N., Hamdy, F. C., Neal, D. E. & Mellon, J. K. Neural network analysis of clinicopathological and molecular markers in bladder cancer. J. Urol. 163, 630-633 (2000). (Pubitemid 30060538)
24. Shariat, S. F., Margulis, V., Lotan, Y., Montorsi, F. & Karakiewicz, P. I. Nomograms for bladder cancer. Eur. Urol. 54, 41-53 (2008).
25. Nguyen, C. T., Stephenson, A. J. & Kattan, M. W. Are nomograms needed in the management of bladder cancer Urol. Oncol. 28, 102-107 (2010).
26. Kiemeney, L. A., Witjes, J. A., Heijbroek, R. P., Verbeek, A. L. & Debruyne, F. M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J. Urol. 150, 60-64 (1993). (Pubitemid 23175971)
27. Chang, S. S. & Cookson, M. S. Non-muscle-invasive bladder cancer: the role of radical cystectomy. Urology 66, 917-922 (2005). (Pubitemid 41587132)
28. Svatek, R. S. et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 107, 898-904 (2011).
29. Torti, F. M. et al. Superficial bladder cancer: the primacy of grade in the development of invasive disease. J. Clin. Oncol. 5, 125-130 (1987). (Pubitemid 17007866)
30. Kwak, C. et al. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. J. Urol. 171, 149-152 (2004). (Pubitemid 37549111)
31. Althausen, A. F., Prout, G. R. Jr & Daly, J. J. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J. Urol. 116, 575-580 (1976).
32. Masood, S., Sriprasad, S., Palmer, J. H. & Mufti, G. R. T1G3 bladder cancer-indications for early cystectomy. Int. Urol. Nephrol. 36, 41-44 (2004). (Pubitemid 38864807)
33. Leissner, J., Koeppen, C. & Wolf, H. K. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J. Urol. 169, 955-960 (2003). (Pubitemid 36188133)
34. Quek, M. L. et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J. Urol. 174, 103-106 (2005). (Pubitemid 40825683)
35. Algaba, F. Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Curr. Opin. Urol. 16, 367-371 (2006). (Pubitemid 44231714)
36. Streeper, N. M. et al. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int. 103, 475-479 (2009).
37. Cho, K. S. et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J. Urol. 182, 2625-2630 (2009).
38. Black, P. C., Brown, G. A. & Dinney, C. P. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol. Oncol. 27, 3-7 (2009).
39. Kassouf, W. et al. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M. D. Anderson Cancer Center experience. Cancer 110, 764-769 (2007). (Pubitemid 47257652)
40. Heudel, P., El Karak, F., Ismaili, N., Droz, J. P. & Flechon, A. Micropapillary bladder cancer: a review of Leon Berard Cancer Center experience. BMC Urol. 9, 5 (2009).
41. Kamat, A. M. et al. Micropapillary bladder cancer: a review of the University of Texas, M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110, 62-67 (2007). (Pubitemid 46986419)
42. Siefker-Radtke, A. O. et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the, M. D. Anderson cancer experience. J. Urol. 172, 481-484 (2004). (Pubitemid 38900183)
43. Shokeir, A. A. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 93, 216-220 (2004).
44. Scosyrev, E., Yao, J. & Messing, E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment Urology 73, 822-827 (2009).
45. Scosyrev, E. et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 108, 693-699 (2011).
46. Izzo, L. et al. A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. Nat. Clin. Pract. Urol. 5, 403-407 (2008). (Pubitemid 352003295)
47. Shanks, J. H. & Iczkowski, K. A. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology 54, 885-900 (2009).
48. Ghoneim, I. A. et al. Neoadjuvant systemic therapy or early cystectomy Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder. Urology 77, 867-870 (2011).
49. Comperat, E. et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology 42, 650-654 (2010).
50. Wright, J. L. et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J. Urol. 178, 2302-2307 (2007). (Pubitemid 350052182)
51. Wallach, J. B., Wang, B. & Sanfilippo, N. High-grade hyperinvasive sarcomatoid urothelial bladder carcinoma demonstrating complete response to bladder-preserving chemoradiation. Curr. Oncol. 16, 55-57 (2009).
52. Hoshi, S. et al. Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy. Int. J. Urol. 14, 79-81 (2007). (Pubitemid 44952588)
53. Mukesh, M., Cook, N., Hollingdale, A. E., Ainsworth, N. L. & Russell, S. G. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int. 103, 747-752 (2009).
54. Amin, M. B. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod. Pathol. 22 (Suppl. 2), S96-S118 (2009).
55. Choong, N. W., Quevedo, J. F. & Kaur, J. S. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 103, 1172-1178 (2005). (Pubitemid 40328087)
56. Knowles, M. A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese Carcinogenesis 27, 361-373 (2006). (Pubitemid 43372866)
57. Wu, X. R. Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer 5, 713-725 (2005).
58. Mhawech-Fauceglia, P., Cheney, R. T. & Schwaller, J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 106, 1205-1216 (2006). (Pubitemid 43363896)
59. Chatterjee, S. J. et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22, 1007-1013 (2004). (Pubitemid 41095032)
60. Wijkstrom, H. et al. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. Br. J. Urol. 81, 686-691 (1998). (Pubitemid 28316631)
61. Kim, J. K., Park, S. Y., Ahn, H. J., Kim, C. S. & Cho, K. S. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 231, 725-731 (2004). (Pubitemid 38668089)
62. Joffe, S. A., Servaes, S., Okon, S. & Horowitz, M. Multi-detector row CT urography in the evaluation of hematuria. Radiographics 23, 1441-1456 (2003).
63. Saksena, M. A., Dahl, D. M. & Harisinghani, M. G. New imaging modalities in bladder cancer. World J. Urol. 24, 473-480 (2006). (Pubitemid 44782301)
64. Swinnen, G. et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur. Urol. 57, 641-647 (2010).
65. Kibel, A. S. et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J. Clin. Oncol. 27, 4314-4320 (2009).
66. Haleblian, G. E. et al. Hydronephrosis as a prognostic indicator in bladder cancer patients. J. Urol. 160, 2011-2014 (1998). (Pubitemid 128703603)
67. Divrik, R. T., Sahin, A., Altok, M., Unlu, N. & Zorlu, F. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J. Urol. 178, 802-806 (2007). (Pubitemid 47211087)
68. Lotan, Y. & Roehrborn, C. G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61, 109-118 (2003). (Pubitemid 36151724)
69. Brown, F. M. Urine cytology. Is it still the gold standard for screening Urol. Clin. North Am. 27, 25-37 (2000). (Pubitemid 30085995)
70. Badalament, R. A. et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60, 1423-1427 (1987). (Pubitemid 17140987)
71. Vrooman, O. P. & Witjes, J. A. Urinary markers in bladder cancer. Eur. Urol. 53, 909-916 (2008).
72. Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666-675 (2001). (Pubitemid 32120143)
73. Stenzl, A. et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol. 59, 1009-1018 (2011).
74. Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): update. J. Urol. 178, 2314-2330 (2007). (Pubitemid 350080987)
75. Badalato, G., Patel, T., Hruby, G. & McKiernan, J. Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer BJU Int. http://dx.doi.org/ 10.1111/j.1464-410X.2010.09893.x.
76. Herr, H. W. The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol. 162, 74-76 (1999). (Pubitemid 29420883)
77. Schwaibold, H. E., Sivalingam, S., May, F. & Hartung, R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 97, 1199-1201 (2006). (Pubitemid 43907321)
78. Miladi, M., Peyromaure, M., Zerbib, M., Saighi, D. & Debre, B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur. Urol. 43, 241-245 (2003). (Pubitemid 36314235)
79. Divrik, R. T., Yildirim, U., Zorlu, F. & Ozen, H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol. 175, 1641-1644 (2006).
80. Shelley, M. D., Mason, M. D. & Kynaston, H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat. Rev. 36, 195-205 (2010).
81. Braasch, M. R., Bohle, A. & O'Donnell, M. A. Intravesical instillation treatment of non-muscle-invasive bladder cancer. Eur. Urol. Suppl. 8, 549-555 (2009).
82. O'Donnell, M. & Boehle, A. Treatment options for BCG failures. World J. Urol. 24, 481-487 (2006). (Pubitemid 44782302)
83. Kamat, A. M. et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J. Urol. 175, 881-885 (2006). (Pubitemid 43200002)
84. Brandau, S. & Suttmann, H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed. Pharmacother. 61, 299-305 (2007). (Pubitemid 47189735)
85. Joudi, F. N., Smith, B. J. & O'Donnell, M. A. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol. 24, 344-348 (2006). (Pubitemid 43963411)
86. Nepple, K. G., Aubert, H. A., Braasch, M. R. & O'Donnell, M. A. Combination of BCG and interferon intravesical immunotherapy: an update. World J. Urol. 27, 343-346 (2009).
87. Sharma, P., Old, L. J. & Allison, J. P. Immunotherapeutic strategies for high-risk bladder cancer. Semin. Oncol. 34, 165-172 (2007). (Pubitemid 46436113)
88. Lamm, D. L. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent, TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124-1129 (2000). (Pubitemid 30169376)
89. Shen, Z., Shen, T., Wientjes, M. G., O'Donnell, M. A. & Au, J. L. Intravesical treatments of bladder cancer: review. Pharm. Res. 25, 1500-1510 (2008).
90. Nepple, K. G. et al. Bacillus Calmette-Guerin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J. Urol. 184, 1915-1919 (2010).
91. Sylvester, R. J., Oosterlinck, W. & van der Meijden, A. P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171, 2186-2190 (2004). (Pubitemid 38625431)
92. Solsona, E. et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J. Urol. 164, 685-689 (2000). (Pubitemid 30637602)
93. Gudjonsson, S. et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection The results of a prospective randomised multicentre study. Eur. Urol. 55, 773-780 (2009).
94. Malmstrom, P. U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur. Urol. 56, 247-256 (2009).
95. Witjes, J. A. & Hendricksen, K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur. Urol. 53, 45-52 (2008). (Pubitemid 350167566)
96. Di Stasi, S. M. et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol. 170, 777-782 (2003). (Pubitemid 36999554)
97. Barlow, L. J., Seager, C. M., Benson, M. C. & McKiernan, J. M. Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. Urol. Oncol. 28, 108-111 (2010).
98. Dalbagni, G., Herr, H. W. & Reuter, V. E. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 60, 822-824 (2002). (Pubitemid 35300346)
99. Chang, S. S., Hassan, J. M., Cookson, M. S., Wells, N. & Smith, J. A. Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J. Urol. 170, 1085-1087 (2003). (Pubitemid 37108084)
100. Sanchez-Ortiz, R. F. et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J. Urol. 169, 110-115 (2003). (Pubitemid 35461564)
101. Gore, J. L. et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-medicare analysis. Cancer 115, 988-996 (2009).
102. Guzzo, T. J. et al. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology 74, 1276-1280 (2009).
103. Jager, W. et al. Early vs delayed radical cystectomy for high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int. http://dx.doi.org/10.1111/j.1464-410X.2010. 09980.x.
104. Bianco, F. J. et al. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol. Oncol. 22, 290-294 (2004).
105. Hassan, J. M., Cookson, M. S., Smith, J. A. Jr, Johnson, D. L. & Chang, S. S. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J. Urol. 172, 882-884 (2004). (Pubitemid 39096413)
106. Joudi, F. N. & O'Donnell, M. A. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr. Opin. Urol. 14, 271-275 (2004). (Pubitemid 39141983)
107. Kulkarni, G. S. et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 115, 5450-5459 (2009).
108. Konety, B. R., Joslyn, S. A. & O'Donnell, M. A. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J. Urol. 169, 946-950 (2003). (Pubitemid 36188131)
109. Herr, H. W. et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol. 167, 1295-1298 (2002). (Pubitemid 34132073)
110. Dhar, N. B. et al. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J. Urol. 179, 873-878 (2008).
111. Stein, J. P. & Skinner, D. G. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol. Clin. North Am. 32, 187-197 (2005). (Pubitemid 40603293)
112. Gofrit, O. N., Zorn, K. C., Steinberg, G. D., Zagaja, G. P. & Shalhav, A. L. The Will Rogers phenomenon in urological oncology. J. Urol. 179, 28-33 (2008). (Pubitemid 350216727)
113. Herr, H. W. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 61, 105-108 (2003). (Pubitemid 36151723)
114. Stein, J. P. & Skinner, D. G. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol. Clin. North Am. 32, 187-197 (2005). (Pubitemid 40603293)
115. Leissner, J. et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J. Urol. 171, 139-144 (2004). (Pubitemid 37549109)
116. Hellenthal, N. J., Ramirez, M. L., Evans, C. P., deVere White, R. W. & Koppie, T. M. Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J. Urol. 181, 2490-2495 (2009).
117. Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003). (Pubitemid 37025405)
118. Loehrer, P. J. Sr et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066-1073 (1992).
119. von der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005).
120. Sternberg, C. N. et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G.-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50-54 (2006). (Pubitemid 41814532)
121. Dogliotti, L. et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur. Urol. 52, 134-141 (2007). (Pubitemid 46803003)
122. David, K. A., Milowsky, M. I., Ritchey, J., Carroll, P. R. & Nanus, D. M. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol. 178, 451-454 (2007). (Pubitemid 47030482)
123. Raj, G. V. et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 117, 276-282 (2011).
124. Gallagher, D. J. et al. Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer 115, 5193-5201 (2009).
125. Sternberg, C. N. et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133, 403-407 (1985). (Pubitemid 15129797)
126. Dreicer, R. Advanced bladder cancer: so many drugs, so little progress: what's wrong with this picture Cancer 113, 1275-1277 (2008).
127. Galsky, M. D. The role of taxanes in the management of bladder cancer. Oncologist 10, 792-798 (2005). (Pubitemid 43152696)
128. Albers, P. et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol. 22, 288-294 (2011).
129. Iyer, G., Milowsky, M. I. & Bajorin, D. F. Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Rev. Anticancer Ther. 10, 1917-1932 (2010).
130. Mamtani, R. & Vaughn, D. J. Vinflunine in the treatment of advanced bladder cancer. Expert Rev. Anticancer Ther. 11, 13-20 (2011).
131. Calabro, F. & Sternberg, C. N. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 55, 348-358 (2009).
132. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202-206 (2005).
133. Winquist, E. et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol. 171, 561-569 (2004). (Pubitemid 38090430)
134. Wheat, J. C. & Lee, C. T. in AUA Update Series 2010 Vol. 29 Lesson 34 (ed. Marshall, F. F.) 338-347 (American Urological Association, 2010).
135. Sternberg, C. N. et al. Can. patient selection for bladder preservation be based on response to chemotherapy Cancer 97, 1644-1652 (2003). (Pubitemid 36350708)
136. Herr, H. W., Bajorin, D. F. & Scher, H. I. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J. Clin. Oncol. 16, 1298-1301 (1998). (Pubitemid 28175743)
137. Perdona, S. et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 112, 75-83 (2008).
138. Sternberg, C. N. et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69, 62-79 (2007). (Pubitemid 46186484)
139. Donat, S. M. et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur. Urol. 55, 177-185 (2009).
140. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 48, 189-201 (2005).
141. Sanchez-Carbayo, M. et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am. J. Pathol. 163, 505-516 (2003). (Pubitemid 36909413)
142. Sanchez-Carbayo, M. Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clin. Chem. 49, 23-31 (2003). (Pubitemid 36078550)
143. Kim, W. J. & Bae, S. C. Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 99, 646-652 (2008).
144. Kim, W. J. & Quan, C. Genetic and epigenetic aspects of bladder cancer. J. Cell Biochem. 95, 24-33 (2005). (Pubitemid 41420212)
145. Matsui, Y. et al. Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Mol. Cancer Ther. 8, 2402-2411 (2009).
146. Shariat, S. F. et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J. Urol. 183, 1744-1750 (2010).
147. Kaufman, D. S., Shipley, W. U. & Feldman, A. S. Bladder cancer. Lancet 374, 239-249 (2009).
148. Habuchi, T. et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66 (Suppl. 1), 64-74 (2005). (Pubitemid 43049609)
149. Stadler, W. M. et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol. 29, 3443-3449 (2011).
150. Smith, S. C. et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 12, 137-143 (2011).
151. Stadler, W. M. et al. Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ-confined node-negative urothelial bladder cancer (UBC) [abstract]. J. Clin. Oncol. 27, 5017 (2009).
152. Golijanin, D. J., Kakiashvili, D., Madeb, R. R., Messing, E. M. & Lerner, S. P. Chemoprevention of bladder cancer. World J. Urol. 24, 445-472 (2006). (Pubitemid 44793611)
153. Lerner, S. P. et al. BCAN Think Tank session 3: Prevention of bladder cancer. Urol. Oncol. 28, 338-342 (2010).
154. Amaral, A. F., Cantor, K. P., Silverman, D. T. & Malats, N. Selenium and bladder cancer risk: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 19, 2407-2415 (2010).
155. Ather, M. H. & Zaidi, M. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables. Urol. J. 6, 189-193 (2009).
156. Fernandez-Gomez, J. et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur. Urol. 60, 423-430 (2011).